Papillary Thyroid Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The papillary thyroid carcinoma (PTC), an epithelial cancer, displays distinct nuclear features as well as follicular cell differentiation. The most typical thyroid tumor also has the best overall prognosis. Despite occasionally having cystic characteristics, the tumor frequently appears as an uneven solid mass. The majority of papillary thyroid cancer cases are in middle-aged adults, with a 3:1 male to female ratio and a median age of 50 years at presentation. Even though pediatric thyroid cancer is uncommon, PTC is still the most common type. For papillary thyroid cancer, surgery is the only curative option. Indirect or fiberoptic laryngoscopy is performed as part of preoperative planning to evaluate airway and vocal cord mobility and to document any unrelated abnormalities.

Description

The papillary thyroid carcinoma (PTC), an epithelial cancer, displays distinct nuclear features as well as follicular cell differentiation. The most typical thyroid tumor also has the best overall prognosis. Even though it occasionally exhibits cystic features, the tumor frequently appears as an uneven solid mass. One of PTC's key characteristics is its ability to infect nearby structures like lymphatics. 10% of patients may already have metastatic illness when they first present. The prognosis is typically good for patients under 45.

Papillary Thyroid Cancer (Epidemiology)

Papillary thyroid carcinoma is the most prevalent type of thyroid cancer, making up 80-85% of cases. A study using the Surveillance, Epidemiology and End Results (SEER) database found that between 1975 and 2012, the incidence of PTC increased from 4.8 to 14.9 per 100,000 people. Papillary thyroid cancer most commonly affects middle-aged adults, with a 3:1 male to female ratio and a median age of 50 years at presentation. Though PTC is uncommon in children, it is still the most common type of thyroid cancer in children. White individuals are impacted more frequently than Black individuals. Thyroid cancers account for just 1.5% of all cancers in adults and 3% of all cancers in children. However, thyroid cancer, which accounts for 3% of all cases, is the seventh most common cancer in women. Despite the fact that there had been an increase in new cases in recent years, from 2014 to 2018, the incidence rate decreased by 2.5% annually, in part due to the adoption of more conservative diagnostic standards. The American Cancer Society (ACS) projects that there will be 43,800 new cases of thyroid cancer in 2022, with 31,940 of those cases affecting women and 11,860 affecting men. The ACS projects that there will be 2230 deaths from thyroid cancer, of which 1160 will be in women and 1070 will be in men. In Hawaii, thyroid cancer affects more Chinese women than any other country. 74-80% of thyroid cancer cases are papillary cancer. Incidences of follicular carcinoma are higher in regions where goiter is more common. Contrary to many other cancers, PTC is typically curable. The prognosis for thyroid cancer is generally very good, and it grows slowly. The mean survival rate after 10 years is between 90% and 100% in very young patients with minimal nonmetastatic disease. Distant spread, like to the lungs or bones, is a very uncommon occurrence. Men are diagnosed with thyroid cancer about a third less frequently than women. Although thyroid cancer can strike anyone at any age, it is most common in people between the ages of 45 and 54; the median age at diagnosis is 51. When compared to follicular thyroid cancer, papillary thyroid cancer tends to affect younger people more frequently, peaking in patients between the ages of 30 and 50.

Papillary Thyroid Cancer -Current Market Size & Forecast Trends

The market for papillary thyroid cancer (PTC) treatment is currently valued at approximately USD 303 million in 2023 and is projected to grow significantly, reaching around USD 1.62 billion by 2034, with a compound annual growth rate (CAGR) of 16.49% from 2024 to 2034. PTC is the most common type of thyroid cancer, accounting for a significant share of thyroid cancer cases, and its treatment options include surgery, radioactive iodine therapy, and targeted therapies. The increasing incidence of thyroid cancer, along with advancements in treatment approaches and rising awareness about early detection, are key factors driving this market growth. As research continues to evolve and new therapeutic strategies are developed, the papillary thyroid cancer market is well-positioned for substantial expansion through 2035.

Surgery is the only curative method for papillary thyroid cancer. To evaluate vocal cord and airway mobility and to record any unrelated abnormalities, indirect or fiberoptic laryngoscopy is used as part of preoperative planning. After having their thyroid surgically removed, patients may receive radioiodine therapy to check for and remove any metastases and leftover thyroid tissue. This procedure is typically carried out for 4-6 weeks following the surgical removal of the thyroid. External beam radiotherapy has been used as adjuvant therapy for papillary thyroid cancer in patients who were older than 45 and had locally invasive diseases. Some increases in 10-year survival rates have been reported as a result of this method. Patients require lifelong thyroid hormone replacement therapy, particularly after a total thyroidectomy. Levothyroxine is given in the course of treatment at a dosage of 2. 5-3. 0,05 mg/kg/d.

Report Highlights

Papillary Thyroid Cancer - Current Market Trends

Papillary Thyroid Cancer - Current & Forecasted Cases across the G8 Countries

Papillary Thyroid Cancer - Market Opportunities and Sales Potential for Agents

Papillary Thyroid Cancer - Patient-based Market Forecast to 2035

Papillary Thyroid Cancer - Untapped Business Opportunities

Papillary Thyroid Cancer - Product Positioning Vis-a-vis Competitors' Products

Papillary Thyroid Cancer - KOLs Insight